|
CN1635900A
(zh)
|
2001-08-28 |
2005-07-06 |
伊莱利利公司 |
Glp-1和基础胰岛素的预混合物
|
|
JP2005508360A
(ja)
|
2001-10-19 |
2005-03-31 |
イーライ・リリー・アンド・カンパニー |
Glp−1およびインスリンの二相混合物
|
|
EP2107069B1
(en)
|
2003-08-05 |
2013-01-16 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
WO2005021841A2
(en)
|
2003-09-03 |
2005-03-10 |
Bioforms |
Methods and apparatus for rapid crystallization of biomolecules
|
|
ES2642214T3
(es)
|
2004-01-21 |
2017-11-15 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
|
WO2006008238A1
(en)
*
|
2004-07-16 |
2006-01-26 |
Novo Nordisk A/S |
Method for selective acylation
|
|
CN102772788B
(zh)
*
|
2004-10-05 |
2017-06-06 |
诺和诺德公司 |
包含结晶的胰岛素和溶解的胰岛素的药物制剂
|
|
EP2505593A1
(en)
|
2005-12-28 |
2012-10-03 |
Novo Nordisk A/S |
Compositions comprising an acylated insulin and zinc and method of making the said compositions
|
|
WO2007081824A2
(en)
*
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
|
JP5550338B2
(ja)
*
|
2006-07-31 |
2014-07-16 |
ノボ・ノルデイスク・エー/エス |
ペグ化持続型インスリン
|
|
EP2074141B1
(en)
|
2006-09-22 |
2016-08-10 |
Novo Nordisk A/S |
Protease resistant insulin analogues
|
|
ES2554773T3
(es)
*
|
2006-10-04 |
2015-12-23 |
Case Western Reserve University |
Insulina y análogos de la insulina resistentes a la fibrilación
|
|
WO2008132224A2
(en)
|
2007-04-30 |
2008-11-06 |
Novo Nordisk A/S |
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
|
|
CN101677947B
(zh)
|
2007-06-13 |
2013-07-17 |
诺沃-诺迪斯克有限公司 |
包含胰岛素衍生物的药物制剂
|
|
US9150633B2
(en)
*
|
2007-08-15 |
2015-10-06 |
Novo Nordisk A/S |
Insulin analogues with an acyl and alkylene glycol moiety
|
|
NZ586590A
(en)
*
|
2008-01-09 |
2012-06-29 |
Sanofi Aventis Deutschland |
Insulin analogues or derivatives having an extremely delayed time-action profile
|
|
JP5695909B2
(ja)
*
|
2008-01-09 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
|
|
US20110065633A1
(en)
|
2008-01-30 |
2011-03-17 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
|
CN101970477B
(zh)
|
2008-03-14 |
2014-12-31 |
诺沃-诺迪斯克有限公司 |
蛋白酶稳定的胰岛素类似物
|
|
PT2910570T
(pt)
|
2008-03-18 |
2017-01-24 |
Novo Nordisk As |
Análogos de insulina acilados, estabilizados contra proteases
|
|
WO2009129250A2
(en)
|
2008-04-14 |
2009-10-22 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
|
RU2010147076A
(ru)
*
|
2008-04-22 |
2012-05-27 |
Кейз Вестерн Ризев Юнивесити (Us) |
Аналоги инсулина специфичные к изоформам
|
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
US9200053B2
(en)
|
2008-07-31 |
2015-12-01 |
Case Western Reserve University |
Insulin analogues containing penta-fluoro-Phenylalanine at position B24
|
|
KR20120129875A
(ko)
|
2008-07-31 |
2012-11-28 |
케이스 웨스턴 리저브 유니버시티 |
염소화 아미노산을 갖는 인슐린 유사체
|
|
AU2013237740B2
(en)
*
|
2008-07-31 |
2016-06-02 |
Case Western Reserve University |
Insulin analogues containing penta-fluora-phenyalanine at position B24
|
|
RU2555557C2
(ru)
*
|
2008-07-31 |
2015-07-10 |
Кейз Вестерн Ризев Юнивесити |
Инсулин, стабилизированный галогеном
|
|
DK3228320T3
(da)
|
2008-10-17 |
2020-03-09 |
Sanofi Aventis Deutschland |
Kombination af et insulin og en glp-1-agonist
|
|
AU2009309623B9
(en)
|
2008-10-30 |
2014-10-02 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
|
BRPI0823377A2
(pt)
|
2008-12-15 |
2016-09-27 |
Zealand Pharma As |
análogos de glucagon
|
|
DK2370461T3
(da)
|
2008-12-15 |
2013-12-16 |
Zealand Pharma As |
Glucagonanaloger
|
|
EP2376520B1
(en)
|
2008-12-19 |
2014-02-12 |
Indiana University Research&Technology Corporation |
Insulin analogs
|
|
US20110237493A1
(en)
*
|
2008-12-19 |
2011-09-29 |
Indiana University Research And Technology Corporation |
Dipeptide linked medicinal agents
|
|
AU2009335713A1
(en)
*
|
2008-12-19 |
2010-07-15 |
Indiana University Research And Technology Corporation |
YL-based insulin-like growth factors exhibiting high activity at the insulin receptor
|
|
WO2010071807A1
(en)
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
CA2744558A1
(en)
*
|
2008-12-19 |
2010-07-15 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
|
JP6054742B2
(ja)
|
2009-07-13 |
2016-12-27 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
BR112012002934B1
(pt)
*
|
2009-08-11 |
2021-12-21 |
Biocon Limited |
Processos cromatográficos e seus compostos purificados
|
|
US8399407B2
(en)
|
2009-09-17 |
2013-03-19 |
Case Western Reserve University |
Non-standard insulin analogues
|
|
JP5119232B2
(ja)
*
|
2009-11-06 |
2013-01-16 |
株式会社マルハニチロ食品 |
プロタミンの定量法
|
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
|
PL3417871T3
(pl)
|
2009-11-13 |
2021-06-14 |
Sanofi-Aventis Deutschland Gmbh |
Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
|
|
CA2783763A1
(en)
*
|
2009-12-11 |
2011-06-16 |
Case Western Reserve University |
Insulin analogues with chlorinated amino acids
|
|
AR081066A1
(es)
*
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
|
CN103068842B
(zh)
|
2010-06-16 |
2016-10-19 |
印第安纳大学研究及科技有限公司 |
对胰岛素受体具有高活性的单链胰岛素激动剂
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
KR20130102470A
(ko)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
|
|
US9169310B2
(en)
|
2010-06-24 |
2015-10-27 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CA2803164C
(en)
*
|
2010-06-24 |
2018-08-21 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
|
RU2013123515A
(ru)
|
2010-10-27 |
2014-12-10 |
Ново Нордиск А/С |
Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
|
|
PH12013501495A1
(en)
|
2011-01-20 |
2013-09-16 |
Zealand Pharma As |
Combination of acylated glucagon analogues with insulin analogues
|
|
CN103533952B
(zh)
*
|
2011-03-15 |
2017-02-15 |
诺沃—诺迪斯克有限公司 |
包含半胱氨酸置换的人胰岛素类似物和衍生物
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
DK2741765T3
(en)
|
2011-08-10 |
2016-06-13 |
Adocia |
Injectable solution of at least one type of basal insulin
|
|
BR112014004726A2
(pt)
|
2011-08-29 |
2017-04-04 |
Sanofi Aventis Deutschland |
combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
JP6392123B2
(ja)
|
2011-12-20 |
2018-09-19 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
糖尿病治療のためのctp系インスリンアナローグ
|
|
BR112014016889A8
(pt)
|
2012-01-09 |
2017-07-04 |
Adocia |
composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
|
|
US20150299286A1
(en)
*
|
2012-01-20 |
2015-10-22 |
Case Western Reserve University |
Glutamic acid-stabilized insulin analogues
|
|
BR112014025132A2
(pt)
|
2012-04-11 |
2017-07-11 |
Novo Nordisk As |
formulações de insulina
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Gip−glp−1デュアルアゴニスト化合物及び方法
|
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
|
US20150314003A2
(en)
|
2012-08-09 |
2015-11-05 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
|
|
FR3001896B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
CN104981251B
(zh)
|
2012-09-26 |
2018-03-20 |
印第安纳大学研究及科技有限公司 |
胰岛素类似物二聚体
|
|
FR3001895B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
EP2970511B1
(en)
|
2013-03-14 |
2020-09-30 |
Indiana University Research and Technology Corporation |
Insulin-incretin conjugates
|
|
WO2014177623A1
(en)
|
2013-04-30 |
2014-11-06 |
Novo Nordisk A/S |
Novel administration regime
|
|
PT3055325T
(pt)
|
2013-10-07 |
2018-04-06 |
Novo Nordisk As |
Novo derivado de um análogo de insulina
|
|
CA2926314C
(en)
|
2013-10-17 |
2023-08-29 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
FR3013049B1
(fr)
*
|
2013-11-14 |
2015-11-13 |
You-Ping Chan |
Analogue de l'insuline glargine
|
|
AU2015205620A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
|
AU2015205624A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
SG11201604708VA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
|
WO2015196174A1
(en)
|
2014-06-20 |
2015-12-23 |
Greene Howard E |
Infusion delivery devices and methods
|
|
US10385107B2
(en)
|
2014-09-24 |
2019-08-20 |
Indiana Univeresity Researc and Technology Corporation |
Lipidated amide-based insulin prodrugs
|
|
JP6657230B2
(ja)
|
2014-09-24 |
2020-03-04 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
インクレチン−インスリンコンジュゲート
|
|
KR102569743B1
(ko)
|
2014-10-06 |
2023-08-23 |
케이스 웨스턴 리저브 유니버시티 |
이상 단일 사슬 인슐린 유사체
|
|
EP3212218B1
(en)
|
2014-10-29 |
2021-06-30 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
ES2949095T3
(es)
|
2014-12-12 |
2023-09-25 |
Sanofi Aventis Deutschland |
Formulación de relación fija de insulina glargina/lixisenatida
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
|
CA2980978A1
(en)
|
2015-04-16 |
2016-10-20 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
|
AR105616A1
(es)
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
|
FR3052072A1
(fr)
|
2016-06-07 |
2017-12-08 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
PT3554534T
(pt)
|
2016-12-16 |
2021-11-05 |
Novo Nordisk As |
Composições farmacêuticas contendo insulina
|
|
KR20180002062U
(ko)
|
2016-12-28 |
2018-07-06 |
유애자 |
크리스탈이 구비된 조명커버
|
|
FR3070264A1
(fr)
|
2017-08-24 |
2019-03-01 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
FR3083089A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
FR3083088B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
WO2019110625A1
(fr)
|
2017-12-06 |
2019-06-13 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
KR20240171197A
(ko)
|
2017-12-07 |
2024-12-06 |
아도시아 |
pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
|
|
WO2019110773A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
WO2019243628A1
(fr)
|
2018-06-22 |
2019-12-26 |
Adocia |
Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
|
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
|
FR3084585B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
|
|
WO2020115334A1
(fr)
|
2018-12-07 |
2020-06-11 |
Adocia |
Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
|
|
US20200179489A1
(en)
|
2018-12-07 |
2020-06-11 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
|
|
WO2020245470A1
(fr)
|
2019-06-07 |
2020-12-10 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
US12343383B2
(en)
|
2019-07-12 |
2025-07-01 |
Novo Nordisk A/S |
High concentration insulin formulation
|